

Luis Villela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1826424/publications.pdf>

Version: 2024-02-01

38
papers

276
citations

1040056

9
h-index

940533

16
g-index

39
all docs

39
docs citations

39
times ranked

401
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. <i>JCO Global Oncology</i> , 2021, 7, 1151-1166.	1.8	15
2	Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1282-1290.	3.4	10
3	A Novel Prognostic Index for Patients with EBV-DLBCL NOS: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). <i>Blood</i> , 2021, 138, 1436-1436.	1.4	1
4	A Simplified Novel Prognostic Score to Predict Early Mortality and Disease Progression in Patients with Aggressive Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2021, 138, 1404-1404.	1.4	0
5	Serum Albumin and Neutrophil-to-Lymphocyte Ratio, Two Independent Factor Predicting Survival in Patients with Follicular Lymphoma: A Multi-Institutional Retrospective Cohort of 741 FL, from the Latin American Lymphoproliferative Study Group (GELL). <i>Blood</i> , 2021, 138, 4515-4515.	1.4	0
6	Clinicopathological Features and Outcomes of EBV Positive and Negative DLBCL: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). <i>Blood</i> , 2021, 138, 1442-1442.	1.4	2
7	Updated Analysis Confirms Sustained Poor Prognosis of COVID-19 in Patients with Lymphoma in Latin America: A Cohort of 160 Patients from Gell. <i>Blood</i> , 2021, 138, 2520-2520.	1.4	0
8	Clinico-Epidemiological Features of Elderly Patients with Peripheral T-Cell Lymphoma Not Otherwise Specified: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). <i>Blood</i> , 2021, 138, 2468-2468.	1.4	0
9	Biological and Classical Prognostic Factors with Impact on Overall Survival in Patients with Early Stage (I/II) Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). <i>Blood</i> , 2021, 138, 2516-2516.	1.4	0
10	miRNA signature associated with "CHOP refractoriness in patients diagnosed with diffuse large B cell lymphoma. <i>Non-coding RNA Research</i> , 2020, 5, 185-190.	4.6	4
11	A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 637-646.	0.4	3
12	Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL. <i>Journal of Translational Medicine</i> , 2019, 17, 198.	4.4	8
13	A1C diagnostic accuracy for Type 2 diabetes mellitus in North Mexico. <i>Salud Publica De Mexico</i> , 2019, 61, 97.	0.4	0
14	Denaturing high-performance liquid chromatography and principal component analysis for identification of DNA point mutations in breast cancer and lymphoma samples. <i>Journal of Chemometrics</i> , 2018, 32, e3053.	1.3	0
15	Cytotoxic Activity of a Black Bean (<i>Phaseolus vulgaris</i> L.) Extract and its Flavonoid Fraction in Both in vitro and in vivo Models of Lymphoma. <i>Revista De Investigacion Clinica</i> , 2018, 70, 32-39.	0.4	7
16	"Ultrasensitive Reactive C-Protein As an Affordable Biomarker of Quantitative Expression of the BCR-ABL Transcript in Chronic Myeloid Leukemia. an Exploratory Study." <i>Blood</i> , 2018, 132, 5450-5450.	1.4	0
17	Advantages of Drug Selective Distribution in Cancer Treatment: Brentuximab Vedotin. <i>International Journal of Pharmacology</i> , 2017, 13, 785-807.	0.3	3
18	Efficient Gene Selection for Cancer Prognostic Biomarkers Using Swarm Optimization and Survival Analysis. <i>Current Bioinformatics</i> , 2016, 11, 310-323.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Molecular Subtype Classification of Diffuse Large B-Cell Lymphoma By Immunohistochemical Algorithms and Automatic Supervised Classifiers. <i>Blood</i> , 2016, 128, 4229-4229.	1.4	0
20	A PER3 polymorphism is associated with better overall survival in diffuse large B-cell lymphoma in Mexican population. <i>Cancer Biomarkers</i> , 2015, 15, 699-705.	1.7	7
21	Can sTREM-1 predict septic shock & death in late-onset neonatal sepsis? A pilot study. <i>International Journal of Infectious Diseases</i> , 2015, 30, 27-32.	3.3	27
22	GPX3 Level in Serum of Diffuse Large B Cell Lymphoma Patients Is a Predictive Biomarker for Refractoriness Before Treatment. <i>Blood</i> , 2012, 120, 5102-5102.	1.4	0
23	Acute Myeloid Leukaemia. <i>Drugs</i> , 2011, 71, 1537-1550.	10.9	19
24	Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome. <i>Anti-Cancer Drugs</i> , 2010, 21, 469.	1.4	5
25	Mutations In Circadian Rhythm Genes Are Associated with Diffuse Large B-Cell Lymphoma In the Mexican Population. <i>Blood</i> , 2010, 116, 2478-2478.	1.4	0
26	Blood and Bone Marrow Transplantation for Acute Myeloid Leukemia. <i>Clinical Leukemia</i> , 2009, 3, E11-E21.	0.2	3
27	Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. <i>Anti-Cancer Drugs</i> , 2008, 19, 917-920.	1.4	18
28	Primary Prophylaxis Using Peg-Filgrastim Is Useful Preventing Severe Infections and Neutropenia in Patients Diagnosed with Non Hodgkin Lymphoma (NHL). Report of Latin America International Multicenter Study. <i>Blood</i> , 2008, 112, 4663-4663.	1.4	0
29	Aggressive lymphoma involving intracranial epidural region. <i>Journal of Neuro-Oncology</i> , 2007, 83, 181-182.	2.9	4
30	Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 4489-4489.	1.4	0
31	Safety of Intrathecal Rituximab as Prophylaxis or Treatment in CD20+ Acute Lymphoblastic and Aggressive Lymphoma: Report from a Mexican Pilot Study.. <i>Blood</i> , 2006, 108, 4713-4713.	1.4	0
32	Parvovirus B19 and Aplastic Anemia: Case Control Study: Preliminary Report from the ITESM Hematology Study Group.. <i>Blood</i> , 2005, 106, 3765-3765.	1.4	0
33	International Staging System Is Useful for Predicting Survival in Patients with Multiple Myeloma Treated with Chemotherapy ± Interferon vs Intensive Treatment.. <i>Blood</i> , 2005, 106, 5177-5177.	1.4	0
34	Aminoglycoside-associated Severe Renal Failure in Patients with Multiple Myeloma Treated with Thalidomide. <i>Leukemia and Lymphoma</i> , 2004, 45, 1711-1712.	1.3	20
35	Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Haematologica</i> , 2003, 88, 300-5.	3.5	20
36	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. <i>British Journal of Haematology</i> , 2001, 113, 422-424.	2.5	73

#	ARTICLE	IF	CITATIONS
37	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. <i>Cancer</i> , 2001, 91, 1557-1562.	4.1	22
38	Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19. <i>Revista Colombiana De Cancerología</i> , 0, 24, .	0.2	2